Business
Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011
Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n Agreement secures a 2D patented printing technology that will significantly boost production capacity and reduce production costs Further protects CAUMZ™ and HCC011 with four additional manufacturing patents OTTAWA, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Tetra Bio Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced it has signed a definitive manufacturing agreement with Vitiprints LLC, for the commercial scale production of CAUMZ™ and HCC011.  This agreement will further protect CAUMZ™ and HCC011 with four additional patents on manufacturing know-how. VITIPRINTS has developed a proprietary and patented manufacturing system, which can be used by Tetra to manufacture its CAUMZ™ drug on commercial scale.  As part of the manufacturing agreement Tetra has obtained a Vitiprints exclusive license to use this technology for commercial manufacturing CAUMZ™ and HCC-011 at high speed and volume in a manner that will permit it to be used in a vaporization system (CAUMZ™ kit).  This proprietary technology will operate under pharmaceutical GMP (Good Manufacturing Practices) regulations and will ensure a \"pill-to-pill\" consistency that meets inhalation drug standards.  In exchange of this exclusive license Tetra will be required to make milestones and royalty payments on CAUMZ™ sales.  From a financial standpoint this proprietary technology will allow Tetra to reduce it Cost of Goods Sold (COGS) for CAUMZ™ by approximately 75% and will significantly improve CAUMZ™ gross margin. Vitiprints will perform a thorough assessment of the Quantum Facility in Moncton next week with an objective of implementing its technology in the spring for the production of commercial batches.  “The previous technology used for the manufacturing process was excellent but unfortunately it was limited by its maximal batch size capacity.” said Dr. Guy Chamberland, Tetra Bio-Pharma’s CEO and Chief Regulatory Officer.  “In a first phase of implementation, Tetra’s production capacity will increase from 2,500 dosing capsules in a 3-day shift to 100,000 CAUMZ™ dosage units in a single 8-hour shift.  The second phase will involve a ...